Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3048 Somatostatin Analogs or Active Surveillance in Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors

Introduction: Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Schinzari G, Maiorano B, Rossi E, Bianchi A, Chiloiro S,

Keywords: pNET, non-functioning, sporadic, somatostatin analogs, surveillance,

#3033 First-in-Korea Clinical Trial of Lu-177-DOTATATE in Patients with Inoperable, Progressive Somatostatin Receptor-Positive, Metastatic or Locally Advanced Neuroendocrine Tumor (SNU-KB-01)

Introduction: Peptide receptor radionuclide therapy (PRRT) based on Lu-177 DOTATATE is currently used worldwide as a treatment option for neuroendocrine tumor patients. But until now, no PRRT has been approved by the Korea Food and Drug Administration (KFDA). Thus, neuroendocrine tumor patients in Korea have severely limited access to the treatment. To provide treatment opportunities, we have planned a First-in-Korea phase I clinical trial of SNU-KB-01, no-carrier added Lu-177 labeled DOTATATE.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Suh M, Cheon G, Lee D,

Keywords: PRRT, clinical trial, Neuroendocrine tumor, Lu-177-DOTATATE,

#2924 Everolimus in Patients with Advanced Neuroendocrine Neoplasia: A Real-World Study and Analysis of Long Responders

Introduction: Everolimus is a valid therapeutic option for neuroendocrine tumors (NETs); however, data regarding the long responsders in a real-world setting, outside regulatory trials, are scanty.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rinzivillo M

Authors: Rinzivillo M, De Felice I, Magi L, Prosperi D, Iannicelli E,

Keywords: everolimus, neuroendocrine neoplasia, progressive disease, target therapy,

#2247 Efficacy of Oral Chemotherapy with Capecitabine and Temozolomide (Captem) in Patients with Metastatic Neuroendocrine Tumors (NETS). A Single-Institution Experience

Introduction: CapTem chemotherapy regimen is a standard treatment for NETs but limited scientific data on its efficacy and tolerability are available

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Smiroldo V, Carnaghi C, Lania A, Bonifacio C, Pepe G,

Keywords: CapTem, metastatic neuroendocrine tumors,

#2157 A Case Report of a Well-Differentiated Neuroendocrine Tumor in which Sunitinib Treatment Resulted an Effective Response of Disease

Introduction: A case report of no pancreatic well-differentiated neuroendocrine tumor in which sunitinib treatment resulted an effective response of disease

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: SAI R,

Keywords: WD NET, SUNITINIB, NO pNET, Efficacy and safety,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.